Clinical TrialJul 21, 2026, 09:03 AM
Imunon's IMNN-001 Shows Positive Phase 2 Data in Ovarian Cancer
AI Summary
Imunon, Inc. announced positive preliminary data from its ongoing Phase 2 minimal residual disease (MRD) translational clinical trial of IMNN-001 for advanced ovarian cancer. The data showed a deeper antitumor response with IMNN-001, including lower MRD-positive rates, higher circulating tumor DNA (ctDNA) clearance, and a numerically higher rate of patients achieving no evidence of disease compared to the control arm. These findings, combined with a consistent favorable safety profile, reinforce the potential of IMNN-001 and support its advancement in the pivotal Phase 3 OVATION 3 trial.
Key Highlights
- IMNN-001 showed a lower MRD-positive rate of 44% vs. 67% in control arm.
- IMNN-001 achieved a higher ctDNA clearance rate of 87.5% vs. 62.5% in control arm.
- 100% of IMNN-001 patients achieved no evidence of disease (NED) vs. 56% in control arm.
- The Phase 2 MRD study targets 30 patients, with 9 patients in each arm reaching SLL.
- Previous Phase 2 OVATION 2 study showed 14.7-month increase in median overall survival with IMNN-001.
- Previous Phase 2 OVATION 2 study showed 24.2-month increase in median overall survival with PARP inhibitor.
Price Impact
More from IMNN